The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue ...

Oncology Cancer Drugs Market With a projected ... Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold ...

Eli Lilly has launched a new website-based access ... diabetes and migraine drugs, respectively, via telehealth providers 9amHealth and Cove. According to the company, it allows “consistent ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Eli Lilly’s (LLY) shares slumped over 8% on Tuesday after the company projected fourth-quarter sales of its weight-loss drug Zepbound and diabetes treatment Mounjaro to fall short of Wall Street ...

the effects of Medicare’s drug price negotiation, Lilly’s recent disappointing guidance, pricing of the company’s obesity medication Zepbound, and more. We also discuss the latest news from ...

Lilly projects $3.5 billion in revenue from Mounjaro and $1.9 billion for Zepbound. Ricks said the company expects to see continued demand for weight-loss drugs in 2025. As a result, he said ...

Lilly's stock went on a tear in the beginning of 2023, with the company's shares doubling as investors bet on the drug's popularity. The stock stumbled in October last year, after Zepbound's sales ...